1. A Feasibility Study of Durvalumab +/− Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) (n.d.). https://ClinicalTrials.gov/show/NCT03773666
2. A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (n.d.). https://ClinicalTrials.gov/show/NCT02740985
3. A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (n.d.). https://ClinicalTrials.gov/show/NCT04262375
4. A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and or NIR178 in Patients With Advanced Malignancies (n.d.). https://ClinicalTrials.gov/show/NCT03549000
5. A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (n.d.). https://ClinicalTrials.gov/show/NCT04148937